Literature DB >> 31175529

The fading role of triple therapy in patients with atrial fibrillation and acute coronary syndrome: a Bayesian network meta-analysis.

Mohammed Osman1, Babikir Kheiri2, Muhammad Bilal Munir3, Jason A Moreland3, Sudarshan Balla3, Samir Kapadia4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31175529     DOI： 10.1007/s11239-019-01896-9

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  6 in total

1.  2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.

Authors:  Craig T January; L Samuel Wann; Hugh Calkins; Lin Y Chen; Joaquin E Cigarroa; Joseph C Cleveland; Patrick T Ellinor; Michael D Ezekowitz; Michael E Field; Karen L Furie; Paul A Heidenreich; Katherine T Murray; Julie B Shea; Cynthia M Tracy; Clyde W Yancy
Journal:  J Am Coll Cardiol       Date:  2019-01-28       Impact factor: 24.094

2.  An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin K antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI).

Authors:  C Michael Gibson; Roxana Mehran; Christoph Bode; Johnathan Halperin; Freek Verheugt; Peter Wildgoose; Martin van Eickels; Gregory Y H Lip; Marc Cohen; Steen Husted; Eric Peterson; Keith Fox
Journal:  Am Heart J       Date:  2014-12-20       Impact factor: 4.749

3.  Antithrombotic Therapy after Acute Coronary Syndrome or PCI in Atrial Fibrillation.

Authors:  Renato D Lopes; Gretchen Heizer; Ronald Aronson; Amit N Vora; Tyler Massaro; Roxana Mehran; Shaun G Goodman; Stephan Windecker; Harald Darius; Jia Li; Oleg Averkov; M Cecilia Bahit; Otavio Berwanger; Andrzej Budaj; Ziad Hijazi; Alexander Parkhomenko; Peter Sinnaeve; Robert F Storey; Holger Thiele; Dragos Vinereanu; Christopher B Granger; John H Alexander
Journal:  N Engl J Med       Date:  2019-03-17       Impact factor: 91.245

4.  Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation.

Authors:  Christopher P Cannon; Deepak L Bhatt; Jonas Oldgren; Gregory Y H Lip; Stephen G Ellis; Takeshi Kimura; Michael Maeng; Bela Merkely; Uwe Zeymer; Savion Gropper; Matias Nordaby; Eva Kleine; Ruth Harper; Jenny Manassie; James L Januzzi; Jurrien M Ten Berg; P Gabriel Steg; Stefan H Hohnloser
Journal:  N Engl J Med       Date:  2017-08-27       Impact factor: 91.245

5.  Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial.

Authors:  Willem J M Dewilde; Tom Oirbans; Freek W A Verheugt; Johannes C Kelder; Bart J G L De Smet; Jean-Paul Herrman; Tom Adriaenssens; Mathias Vrolix; Antonius A C M Heestermans; Marije M Vis; Jan G P Tijsen; Arnoud W van 't Hof; Jurriën M ten Berg
Journal:  Lancet       Date:  2013-02-13       Impact factor: 79.321

6.  2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA).

Authors:  Gregory Y H Lip; Jean-Phillippe Collet; Michael Haude; Robert Byrne; Eugene H Chung; Laurent Fauchier; Sigrun Halvorsen; Dennis Lau; Nestor Lopez-Cabanillas; Maddalena Lettino; Francisco Marin; Israel Obel; Andrea Rubboli; Robert F Storey; Marco Valgimigli; Kurt Huber
Journal:  Europace       Date:  2019-02-01       Impact factor: 5.214
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.